Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

41
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
41
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

37
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

18
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
18
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

27
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

22
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial.

European heart journal·2026
Same author

Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine.

European journal of heart failure·2026
Same author

T-TEER-interventional repair of tricuspid regurgitation.

Herz·2026
Same author

Ten-year outcome after HeartMate 3 left ventricular assist device implantation.

The Journal of cardiovascular surgery·2026
Same author

Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.

ESC heart failure·2026
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
See all related articles

Related Experiment Video

Updated: Aug 21, 2025

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.6K

[Peripartum Cardiomyopathy].

Tobias Jonathan Pfeffer, Tobias König, Dominik Berliner

    Deutsche Medizinische Wochenschrift (1946)
    |November 17, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Peripartum cardiomyopathy (PPCM) is a rare heart condition affecting women late in pregnancy or postpartum. Early treatment with heart failure therapy and bromocriptine improves outcomes, with most patients recovering heart function.

    More Related Videos

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    4.7K
    Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
    04:55

    Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

    Published on: May 26, 2023

    851

    Related Experiment Videos

    Last Updated: Aug 21, 2025

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
    10:08

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

    Published on: February 17, 2018

    13.6K
    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    4.7K
    Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
    04:55

    Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

    Published on: May 26, 2023

    851

    Area of Science:

    • Cardiology
    • Reproductive Medicine
    • Pharmacology

    Context:

    • Peripartum cardiomyopathy (PPCM) is a serious heart condition affecting women during late pregnancy or postpartum.
    • It involves left ventricular (LV) dysfunction, often with an ejection fraction (EF) below 45%.

    Purpose:

    • To elucidate the pathophysiology of PPCM, focusing on the role of prolactin and oxidative stress.
    • To evaluate the efficacy of bromocriptine in managing PPCM.
    • To provide updated treatment recommendations for PPCM, including cases with cardiogenic shock.

    Summary:

    • Oxidative stress can cause prolactin to form a 16kDa fragment, leading to myocardial dysfunction in PPCM.
    • Bromocriptine, a dopamine agonist, inhibits prolactin release and has shown therapeutic benefits in PPCM.
    • Current guidelines recommend heart failure treatment combined with bromocriptine for PPCM.

    Impact:

    • Early diagnosis and prompt treatment, including bromocriptine, significantly improve prognosis and LV function recovery in most PPCM patients.
    • Patients with cardiogenic shock require specialized care, including mechanical circulatory support and bromocriptine.
    • Understanding PPCM's mechanisms aids in developing targeted therapies for this life-threatening condition.